• Fri. Dec 8th, 2023

Latest Developments in Health Care Market Negotiations


Nov 21, 2023

Analysts at Jefferies have warned that Bayer is facing challenges on multiple fronts, which are pushing the need for strategic options. A halt to a late-stage clinical trial of experimental cardiovascular drug asundexian pushes financial risk to the edge, while share-price falls increase sensitivity to rising provisions and potential trial losses in a legal battle over its Roundup weedkiller. This suggests that the German pharmaceutical-and-agricultural group might need to sell assets and scrap dividends to buy time. However, this may not be enough to enable large-scale investments needed in its pharma business, Jefferies says. The research firm has cut its recommendation on the stock from buy to hold. Despite this, shares are trading 0.3% higher following Monday’s heavy losses.

Leave a Reply